首页> 外文OA文献 >FRI0189 Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaire®-ra)

【2h】

FRI0189 Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaire®-ra)

机译：Fri0189生物仿生候选BI 695501和Adalimalab发起者参考产物中度至严重的活性类风湿性关节炎患者的类似疗效和安全性：III期临床研究的24周结果（Voltaire®-ra）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
S Cohen; A Alonso-Ruiz; PA Klimiuk; E Lee; N Peter; I Sonderegger; D Assudani;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study [J] . Cohen Stanley B., Alonso-Ruiz Alberto, Klimiuk Piotr A., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第6期

机译：Adalimalab BioSimilar Bi 695501和Humira参考产物的类似疗效，安全性和免疫原性在患者中适度到严重活性的类风湿性关节炎：III期随机伏尔雷对等效研究的结果
2. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar Bl 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext) [J] . Stanley B. Cohen, Niklas Czeloth, Eric Lee, Expert opinion on biological therapy . 2019,第7a12期

机译：具有中度至严重活性的类风湿性关节炎的患者Adalimalab BioSimilar BL 695501和Adalimalab参考产物的长期安全性，疗效和免疫原性：来自第3B期扩展研究的结果（Voltaire-Reext）
3. Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy [J] . Genovese Mark, Weinblatt Michael, Keystone Edward, The Journal of rheumatology . 2017,第6期

机译：尽管甲氨蝶呤治疗，抗药物抗体对比较SB5（Adalimalab BioSimilar）与参考患者的疗效和安全性的影响，从A III阶段研究比较SB5
4. Concise report: Similar efficacy safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study [O] . Stanley B Cohen, Alberto Alonso-Ruiz, Piotr A Klimiuk, -1

机译：简明报告：阿达木单抗BI 695501和Humira参考产品在中度至重度活动性类风湿关节炎患者中的相似功效安全性和免疫原性：来自VOLTAIRE-RA III期随机对照研究的结果
5. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study [O] . Alan Menter, Petr Arenberger, Sigrid Balser, 2020

机译：生物仿真效率的类似疗效，安全性和免疫原性，以及中度至严重的慢性牙菌斑牛皮癣患者中的Adalimalab参考产物：来自随机阶段III伏尔师-PSO研究的结果

FRI0189 Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaire®-ra)

著录项

引文网络

相似文献

相关主题

期刊订阅